SummaryAcetaminophen (APAP)-related acute liver injury/liver failure (ALF) often appears to occur in the setting of substance abuse. We identified two single nucleotide polymorphisms previously associated with drug use disorder in a carefully adjudicated group of APAP ALF patients.

Acetaminophen (APAP)-induced liver injury is the most common cause of acute liver failure (ALF) in American adults,[@bib1] with nearly 500 deaths annually attributed to excessive dosing of this ubiquitous pain reliever. The safe upper limit for daily dosing has variably been thought to be 4000 mg/day or possibly less.[@bib2] Excessive APAP dosing can occur with intent of self-harm (suicide attempt) or unintentionally while seeking pain relief, typically for a period of several days by using increased amounts each day.[@bib3], [@bib4] Early on, an association was made between alcohol abuse and APAP unintentional overdoses, referred to initially as therapeutic misadventure.[@bib5] Both intentional and unintentional APAP overdoses have been shown to be associated with substance abuse of both alcohol and opioids, particularly the opioid (hydrocodone/acetaminophen) combination products.[@bib6] In 1 study of 275 APAP-related ALF patients, 55% had a history of alcohol use and 35% a history of alcohol abuse, and 53% had taken an opioid-APAP combination product.[@bib4] In a follow-up study of a larger cohort of 306 APAP toxicity survivors, 55% had a history of psychiatric disease compared with only 27% of non-APAP survivors, 46% of APAP patients had a history of prior substance abuse vs 15% of non-APAP patients, and 14% had a specific history of injection drug use vs 8% for the non-APAP group.[@bib7] Understanding what determines these behaviors might lead to better identification of high-risk patients and development of prevention strategies.

With either intentional or unintentional etiologies, critical behavioral differences could lead to high-risk behaviors. Impulsivity is a character trait defined as "acting suddenly in an unplanned manner to satisfy a desire," ie, not thinking things through to understand the potential impact of a decision. More recently, impulsivity has been recognized as a measurable trait that is correlated with a variety of addictive behaviors.[@bib8] We have recently shown that higher impulsivity scores on the Barratt impulsivity scale are detected in both intentional and unintentional APAP overdoses when compared with control populations (Sanders C, Lee WM, unpublished data, submitted for publication).

During the last 15 years numerous single nucleotide polymorphisms (SNPs) have been found to be associated with addictive behavior, including impulsivity.[@bib8], [@bib9], [@bib10] Many of these SNPs are in genes associated with the stress response, including the genes involved in hormonal systems of the hypothalamic/pituitary/adrenal axis.[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18] For example, the μ-opioid receptor gene, *OPRM1*, has polymorphisms, specifically A118G, that have been linked to increased vulnerability/susceptibility to alcohol and opioid addiction.[@bib11], [@bib14], [@bib15], [@bib19] The μ-opioid receptor is used by both exogenous and endogenous opiates and can exert control over stress responsivity, addiction, and withdrawal. We hypothesized that this polymorphism or others that are related may have an impact in patients with APAP overdoses, especially in patients who have multiple substance dependencies. Furthermore, we speculated that the genetic association may be stronger or more apparent in subjects with intentional APAP overdose compared with those with nonintentional overdose. Thus, variations in several of these genes that alter the host's ability to respond to stressful situations may indeed correlate with the observed tendency of addictive behavior.

The Acute Liver Failure Study Group (ALFSG) ([ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0010}: [NCT00518440](ctgov:NCT00518440){#intref0015}) has been prospectively identifying and studying the etiologies, presenting features, and clinical outcomes of adults with ALF during the past 17 years while collecting biosamples---serum, plasma, and DNA. During this time period, ALFSG has enrolled more than 3000 subjects in its registry, 46% of whom suffered from severe or fatal APAP liver injury. Because stress and the response to stress are closely linked to addictive behavior and APAP toxicity patients have frequently been identified as substance abusers, we sought to determine whether specific variants in stress-related genes are over-represented in an APAP overdose cohort compared with population controls. By using DNA from 229 of these APAP subjects, we sought to identify whether selective variants in genes related to stress/impulsivity and addiction are associated with APAP overdose cases, because these findings might shed light on the patients' tendency to abuse APAP products.

Methods {#sec1}
=======

Patients {#sec1.1}
--------

Among the 1669 subjects who were enrolled in the ALFSG registry database between January 1, 2002 and December 31, 2013 according to principles established in the initial ALFSG report,[@bib1] we selected a consecutive group of patients with unequivocal APAP in whom DNA had also been collected as part of enrollment. Subjects in the overall adult ALFSG registry were enrolled from 33 academic centers in the United States and met criteria for ALF, namely coagulopathy (international normalized ratio ≥ 1.5) and grade 1--4 of hepatic encephalopathy, within 26 weeks of the first symptoms, without overt underlying liver disease. Because patients enrolled are by definition encephalopathic, written informed consent was obtained from the legal next of kin in each case. Demographic, clinical, laboratory, radiologic, and outcomes data were recorded prospectively. For the purpose of the present study, we selected only patients who self-reported as white.

Etiologic diagnoses were made by each study site's primary investigator on the basis of the history and clinical presentation and laboratory, radiographic, and, when available, liver biopsy results. Further adjudication was provided by using an algorithm for confirmation of APAP overdoses developed by the ALFSG causality subcommittee. The algorithm includes the following specific criteria: a history of APAP ingestion, detection of APAP in plasma, biochemical pattern that is consistent with APAP toxicity with high serum aminotransferase levels (≥1000 IU/L) along with total bilirubin \<10.0 mg/dL at presentation, and, if available, presence of APAP-Cys adducts. These criteria have been validated previously in the ALFSG cohort.[@bib4] All subjects were considered to fit the patient phenotype as highly likely/definite APAP toxicity if they met the criteria for history of ingestion and/or parent compound detectable, with appropriate biochemistries as outlined.

Intentionality (intentional/suicidal/single time point vs unintentional \[typically for pain relief, suicide denied\]) was determined by the site investigator on the basis of findings outlined in Schiødt et al.[@bib3] The control subjects (n = 208) were healthy volunteers ascertained by the Laboratory of the Biology of Addictive Diseases at the Rockefeller University who were previously genotyped on a custom Illumina addiction array for other studies.[@bib13], [@bib17]

Genotyping {#sec1.2}
----------

### Genes/single nucleotide polymorphism selection {#sec1.2.1}

Nine genes were selected on the basis of their known involvement with impulsivity and/or stress responsivity. A total of 21 SNPs from these 9 genes were selected on the basis of previous reports of potential functionality and/or association with impulsivity and stress responsivity ([Table 1](#tbl1){ref-type="table"}). These SNPs were chosen because they were previously found to be associated with heroin and/or cocaine dependence or show changes in their gene expression when exposed to the drug. The μ-opioid receptor (*OPRM1)* variants, rs1799971 (A118G) and rs1799972 (C17T), have previously been linked to both alcohol and heroin addiction.[@bib14], [@bib15], [@bib19], [@bib20] We have previously shown the catechol-O-methyltransferase (*COMT*) variants, rs4680 and rs4818, to be associated with opioid dependence.[@bib21] The variants in FK506 binding protein 5 (*FKBP5*), galanin (*GAL*), arginine vasopressin (*AVP*), arginine vasopressin receptor 1A (*AVPR1A*), corticotropin releasing factor (*CRH*), and CRH receptors 1 and 2 (*CRHR1* and *CRHR2*) were chosen for study because they have been found to be associated with a greater vulnerability for dependence, or they are in high-linkage disequilibrium with an SNP that was found to be associated with addiction.[@bib22]

Genotyping {#sec1.3}
----------

The *OPRM1* SNPs, both located in exon 1, were genotyped by Sanger sequencing a 300--base pair region of the DNA that was first amplified by polymerase chain reaction. Each sequence was manually evaluated for determination of the genotype at the 2 *OPRM1* variants. Genotyping of the remaining variants for the case samples was performed by using TaqMan SNP genotyping assays (Life Technologies, Carlsbad, CA) following the manufacturer's recommended protocol. The end-point reactions were scanned and then analyzed on an ABI Prism 7900HT Sequence Detection System (Life Technologies). All TaqMan genotype data were visually inspected for quality. The control samples were genotyped by using a custom Illumina array as described.[@bib17]

Statistical Analysis {#sec1.4}
--------------------

Association tests were carried out between the following groups: intentional vs unintentional overdoses, unintentional vs controls, and all overdose cases (intentional, unintentional, and unknown) vs controls with PLINK v 1.9. Deviations from Hardy-Weinberg equilibrium were checked by χ^2^ test with a critical limit of significance of *P* values \<.001 (taking into account Bonferroni correction for multiple SNPs). In addition, SNPs with a minor allele frequency of less than 0.05 were excluded from further analysis. Association analysis was carried out by logistic regression that considered 3 models of inheritance: recessive, dominant, and additive. The nominal significance level was computed according to 2 different methods within each association model: first, from logistic regression (*p0*) based on the asymptotic distribution of the test statistic (*t* from Wald test); second, by permutation analysis (EMP1) that compares the observed statistic with 100,000 statistics obtained in permutations in the correspondent SNP. To control the family-wise error rate when testing multiple SNPs, the observed statistic was compared with the maximum of permuted statistics over all SNPs (EMP2).

Results {#sec2}
=======

The study group met stringent criteria for APAP diagnosis to be included ([Table 2](#tbl2){ref-type="table"}). In addition to clinical criteria, all 43 that were tested were positive for the presence of APAP-Cys adducts, confirming a toxic ingestion.[@bib23], [@bib24] Selected clinical data are shown in [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}, divided by intentional, unintentional, and unknown overdose type as described above. The proportion giving a history of alcohol and/or drug abuse or having positive toxicology screening was similar to prior studies. Overall, recorded evidence for abuse of alcohol, opiates, or other drugs of abuse (principally cocaine) was greater than 30%. Among intentional cases, 34 of 99 were believed to have used only 1 of the 3 categories of drugs of abuse listed, 18 took 2, and 3 were positive in all 3 categories. Likewise, among the unintentional group, 45 were found to have used only 1 drug of abuse, 23 had taken 2 classes, and 5 were found to have used 3 types of abuse agents.

The SNPs genotyped are listed in [Table 1](#tbl1){ref-type="table"}. Of these, one SNP, *OPRM1* rs1799972 (C17T), was excluded on the basis of minor allele frequency \<.05. None of the SNPs in the study significantly violated Hardy-Weinberg equilibrium. Two SNPs, rs2282018 in *AVP* and rs11174811 in *AVPR1A*, showed significant association of genotype with APAP overdose when all overdose cases were compared with controls ([Table 1](#tbl1){ref-type="table"}, bold highlight). The SNPs are in an intron and the 3\' untranslated region, respectively, on chromosome 12. The common alleles, T for *AVP* SNP rs2282018 (frequency, 0.58) and C for *AVPR1A* SNP rs11174811 (frequency, 0.72), are the risk alleles. The significant associations were detected under dominant model of inheritance with odds ratios of 1.89 and 1.64, respectively. No other significant associations were detected, and there were no differences observed when the unintentional group was considered separately and compared with the intentional overdose or control groups (data not shown).

Discussion {#sec3}
==========

In the present study, we analyzed genotypes of carefully characterized APAP overdose subjects who had experienced severe liver injury, because both unintentional and intentional overdosing appears to represent high-risk behaviors. The 2 SNPs we identified in the *AVP* gene and the gene of one of its receptors, *AVPR1A,* have previously been associated with drug use disorders.[@bib16], [@bib17] One of these studies[@bib17] used the same control sample that was used in the current study but a different case sample. We did not observe differences in the gene frequency between the intentional and unintentional groups. This could relate to the relatively small sample sizes, or that both groups, as noted, are associated with drug use disorders and impulsivity.[@bib4], [@bib6], [@bib7]

Analysis of a limited and select group of candidate systems of genes that are associated with drug use behavior allowed us to narrow our focus, providing a wider approach than specific targeted SNPs but a narrower one than conventional genome-wide association studies. *AVPR1A* receptors are located throughout the brain and may serve several functions, but they specifically are associated with stress responsivity, how the pituitary-adrenal axis responds to stress. *AVPR1A* variants have been studied extensively and show strong associations with several social behaviors including sibling conflict and autism.[@bib16], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29] The *AVPR1A* SNP rs11174811 identified in the current study is specifically thought to be associated with potential seed recognition sites for microRNAs miR-526b and miR-578 and has been shown to be functional in vitro.[@bib28] Disruption of microRNA binding by the *AVPR1A* rs11174811 risk allele appears to confer poorer response to stress as shown in a variety of settings.[@bib16] The functionality of *AVP* SNP rs2282018 is unknown; however, arginine vasopressin ligands and receptors compose the pituitary axis for at least some forms of stress responses.[@bib29]

Although highly popular, APAP is a dose-related toxin with a relatively narrow therapeutic window, resulting in frequent overdosing in certain settings such as unrelieved pain and where the perception is of its great safety. The tendency to display impulsive behavior and to use 1 or more additional substances including alcohol and the combination opioid/acetaminophen products has been well-recognized, conferring increased risk associated with both suicidal and unintentional overdoses.[@bib4], [@bib6], [@bib7] Subjects in the present study were selected for the specific phenotype of APAP ALF by using a detailed algorithm developed by the ALFSG, supplemented by the APAP adduct assay, to provide a high degree of certainty that APAP toxicity was present and caused the liver failure in the patients studied.[@bib23], [@bib24] It is noteworthy that most of the SNPs examined encode for stress responsivity and the tendency to addictive behaviors across the drug use disorder spectrum: alcohol, opiates, and cocaine.[@bib16]

Several unrelated SNPs have been identified that encode for increased sensitivity to APAP toxicity, involving polymorphisms in either the cytochrome P450 or UDP-glucuronosyltransferase genes.[@bib30], [@bib31] These SNPs were not examined here. They might be important in certain patients who are susceptible to liver injury after ingesting less than 4 g/day, the maximum accepted level for safe APAP ingestion; however, this remains controversial. Such patients are infrequent and unlikely to account for the relatively common occurrence of ALF that is in association, for the most part, with documented overdoses of significant proportion.[@bib5]

We conclude that APAP ALF patients, who are known to have a propensity for impulsivity and high-risk behavior, have higher frequency of certain genetic variants associated with drug use disorders. These variants have been previously shown to relate in part to altered stress responsivity. This clinical association in our population is largely confined to the *AVP* and *AVPR1A* gene loci.[@bib16], [@bib17], [@bib29] These initial observations should now be confirmed in a larger study of carefully selected APAP overdose patients.

The Acute Liver Failure Study Group investigators during the period the patient data and DNA were collected included Adrian Reuben, Robert J. Fontana, Timothy Davern, Brendan McGuire, R. Todd Stravitz, Valerie Durkalski, Iris Liou, Oren Fix, Michael Schilsky, Daniel Ganger, MD, Raymond T. Chung, David Koch, K. Rajender Reddy, and Lorenzo Rossaro.

**Conflicts of interest** The authors disclose no conflicts.

**Funding** Supported by NIDDK U-01-DK58369, W.M.L., principal investigator, and a grant to M.J.K. from the Dr. Miriam & Sheldon G. Adelson Medical Research Foundation. The testing for acetaminophen adducts was performed in the laboratory of Dr Laura James, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute, Little Rock, AR.

###### 

List of SNPs Evaluated

  Gene       SNP          CHR   Position    Location   Alleles   MAF    Model   *p*~*0*~   EMP1    EMP2    OR (95% CI)
  ---------- ------------ ----- ----------- ---------- --------- ------ ------- ---------- ------- ------- -------------------
  *AVP*      rs2282018    20    3064949     Intronic   T/C       0.42   Dom     **.028**   0.030   0.258   1.89 (1.07--3.34)
             rs2740204    20    3062467     Intronic   C/A       0.40   Dom     .104       0.099   0.832   
  *AVPR1A*   rs11174811   12    63540476    3′ UTR     C/A       0.18   Dom     **.018**   0.015   0.252   1.64 (1.08--2.50)
             rs3021529    12    63545680    5′ UTR     C/T       0.15   Dom     .053       0.044   0.589   
  *COMT*     rs4818       22    19951207    Intronic   C/G       0.41   Rec     .383       0.357   0.999   
             rs4680       22    19951271    Intronic   G/A       0.49   Rec     .829       0.821   1       
  *CRH*      rs6996265    8     67086350    3′UTR      G/A       0.11   Rec     .181       0.141   0.948   
             rs3176921    8     67091379    Promoter   T/C       0.11   Rec     .115       0.102   0.727   
             rs6472257    8     67092180    Promoter   G/A       0.10   Rec     .181       0.141   0.948   
  *CRHR1*    rs81189      17    43894798    Intronic   G/C       0.22   Dom     .554       0.566   1       
             rs242939     17    43895579    Intronic   T/C       0.49   Dom     .989       0.999   1       
             rs8072451    17    44282654    Intronic   C/T       0.07   Dom     .543       0.522   1       
  *CRHR2*    rs2284217    7     30713608    Intronic   C/T       0.22   Dom     .106       0.112   0.842   
  *FKBP5*    rs3800373    6     35542476    3′ UTR     A/C       0.31   Dom     .366       0.364   0.999   
             rs7757037    6     35548236    Intronic   G/A       0.45   Dom     .580       0.595   1       
             rs1360780    6     35607571    Intronic   C/T       0.32   Dom     .358       0.356   0.999   
             rs9470080    6     35646435    Intronic   C/T       0.33   Dom     .265       0.293   0.993   
  *GAL*      rs694066     11    68452985    Intronic   C/T       0.06   Dom     .405       0.390   1.000   
             rs3136541    11    68457943    Intronic   T/C       0.33   Dom     .138       0.119   0.909   
  *OPRM1*    rs1799971    6     154360797   Intronic   A/G       0.13   Rec     .418       0.479   1.000   

NOTE. The two *p*~o~ values in bold are the only associations found to be nominally significant. OR above 1 represents risk effect of the major allele. Alleles are listed as major/minor.

Chr, chromosome; CI, confidence interval; DOM, dominant; EMP1, point-wise empirical *P* value obtained by permutation; EMP2, empirical *P* value that controls for multiple SNPs; MAF, minor allele frequency; OR, odds ratio; *p*~o~, technical *P* value obtained from logistic regression; REC, recessive.

###### 

Age, Gender, and History of Opioid Use, Other Drug Abuse, and Alcohol Use or Abuse for the Overall APAP Group and Subgroups

                      All (N = 229)   Intentional (N = 99)   Unintentional (N = 98)   Unknown (N = 32)                    
  ------------------- --------------- ---------------------- ------------------------ ------------------ ---- ------ ---- ------
  Age, *y* (median)   37              34                     38                       50                                  
                      N               *%*                    N                        *%*                N    *%*    N    *%*
  Gender (female)     173             75.6                   73                       73.7               77   78.6   23   71.8
  Opioid use          77              33.6                   19                       19.2               45   45.9   13   59.4
  Other drug abuse    70              30.6                   33                       33.3               28   28.6   9    28.1
  EtOH use            84              36.7                   33                       33.3               40   40.8   11   34.4
  EtOH abuse          69              30.1                   27                       27.3               33   33.7   9    28.1

NOTE. Of the 229 APAP subjects, 197 were classifiable as intentional or unintentional, with 32 remaining as unknown type.

EtOH abuse, \>4 drinks daily or \>14 drinks per week; EtOH (alcohol) use, 1--4 drinks daily or \<14 per week (16 mg/drink); other drug abuse, history or toxicology screen positive for cocaine, benzodiazepines, other non-specified polysubstances.

###### 

Laboratory Data for the Same APAP Groups

                                                         All   Intentional   Unintentional   Unknown                                                 
  ------------------------------------------------------ ----- ------------- --------------- --------- ------ ------- ---- ------ ------ ---- ------ ------
  AST (*IU/L*)                                           229   5734          6933            99        6333   7670    98   5423   6441   32   4123   6158
  ALT (*IU/L*)                                           229   4867          5779            99        5864   6573    98   4538   5424   32   3810   4412
  T Bili (*mg/dL*)                                       229   3.9           4.5             99        3.9    4.1     98   3.9    4.0    32   6.4    7.1
  APAP level (*mg/L*)                                    217   32.0          79.6            96        69.3   119.4   91   24.0   44.1   30   42.0   59.7
  Adduct[a](#tbl3fna){ref-type="table-fn"} (*nmol/mL*)   43    9.9           13.0            21        11.0   15.9    19   7.4    9.7    3    17.1   14.5

NOTE. Values \>1 nmol APAP-Cys/mL are considered significant and specific for APAP hepatotoxicity.[@bib20]

ALT, alanine aminotransferase; AST, aspartate aminotransferase; T Bili, total bilirubin.

Adduct levels are measured by high-pressure chromatography with electrochemical detection.
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